within Pharmacolibrary.Drugs.V_Various.V04C_OtherDiagnosticAgents.V04CX10_Pafolacianine;

model Pafolacianine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.9166666666666666e-06,
    adminDuration = 600,
    adminMass = 0.025 / 1000000,
    adminCount = 1,
    Vd = 0.00015,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00016,
    k12 = 2.1e-06,
    k21 = 2.1e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Pafolacianine</td></tr><tr><td>ATC code:</td><td>V04CX10</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>0.025</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.15</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.15</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Pafolacianine is a fluorescent imaging agent used during surgery to identify malignant and non-malignant ovarian cancer lesions. It targets folate receptor-positive tissues and is used as an adjunct to standard intraoperative methods. Pafolacianine is approved in the USA under the trade name Cytalux for use in certain adult patients with ovarian cancer.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics described for adult patients with ovarian cancer undergoing intraoperative imaging; values primarily based on FDA clinical trial labeling.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V04CX10 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Pafolacianine;
